Talk:Entinostat

07-OCT-2011

The reference for HDACi isoform selectivity (the patent) is not for Entinostat, but for sulfonyl containing HDACi. — Preceding unsigned comment added by Gryderart (talk • contribs) 00:02, 7 October 2011 (UTC)

Some proposed changes

Add after "There is an ongoing phase II trial studying the effect of entinostat on Hodgkin's lymphoma."

There are several other ongoing trials with entinostat: Entinostat with Immune Checkpoint Inhibitors (sponsored by Syndax Pharmaceuticals, Inc.) • (ENCORE 601/ KEYNOTE 142) A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC), With Expansion Cohorts in Patients With NSCLC, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer.[NCT02437136] https://www.clinicaltrials.gov/ct2/show/NCT02437136 o Interim results presented at the World Conference on Lung Cancer (WCLC) 2018 for the NSCLC patient cohort (N = 76) showed 11% objective response rate (ORR) and a median duration of response of 5 months with an acceptable safety profile. Response was associated with a higher median baseline level of peripheral classical monocytes. Hellmann M, Janne P, Opyrchal M, et al Presented at WCLC 2018 (abstr OA05): https://wclc2018.iaslc.org/wp-content/uploads/2018/09/WCLC2018-Abstract-Book_vF-LR-REV-SEPT-25-2018.pdf o Interim results presented at the American Society of Clinical Oncology (ASCO) 2018 for the melanoma cohort (N = 34) showed 18% ORR and a median duration of response of 9 months with an acceptable safety profile. Agarwala S., Moschos S, Johnson M, et al. Presented at ASCO 2018 (abstr 9530). o Interim results presented at ASCO 2018 for the colorectal cancer cohort (N = 16) showed progression-free survival of 12.3 weeks, duration of response greater than 7 months and an acceptable safety profile. Azad N, Shirai K, McRee A, et al. Presented at ASCO 2018 (abstr 3557). • (ENCORE 602) A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with Metastatic Triple Negative Breast Cancer, with a Phase 1b Lead in Phase.[NCT02708680] https://www.clinicaltrials.gov/ct2/show/NCT02708680 • (ENCORE 603) A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in. [NCT02915523] https://www.clinicaltrials.gov/ct2/show/NCT02915523

Entinostat in HR+ Breast Cancer (sponsored by the National Cancer Institute) • (E2112). A Randomized Phase 3 Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor Positive Advanced Breast Cancer. [NCT02115282] https://www.clinicaltrials.gov/ct2/show/NCT02115282

Current reference 6 does not lead to a current link. Propose change to http://www.syndax.com/pipeline/entinostat/ retrieved 01/15/2019. KScientific (talk) 18:10, 15 January 2019 (UTC)KScientific

Reply 15-JAN-2019

  Edit request declined  

1. The requested content is insufficiently paraphrased from the source material. Added content must be placed in an editor's own words using an editor's own phrasing, per WP:CLOSEPARAPHRASE.
2. Texts should be written for everyday readers, not just for academics. An article's prose should reflect common usage, not academic terminology, whenever possible, per WP:NOTJOURNAL.

Regards,  Spintendo  19:53, 15 January 2019 (UTC)

Add after "There is an ongoing phase II trial studying the effect of entinostat on Hodgkin's lymphoma." There are also ongoing trials in lung cancer, melanoma, colorectal cancer, ovarian cancer and breast cancer. There are several studies investigating entinostat combined with checkpoint inhibitors. There is a phase Ib/II trial studying the effect of entinostat plus pembrolizumab on non-small cell lung cancer, melanoma and colorectal cancer patients. https://www.clinicaltrials.gov/ct2/show/NCT02437136. There is also a phase II trial studying the effect of atezolizumab with or without entinostat on triple negative breast cancer https://www.clinicaltrials.gov/ct2/show/NCT02708680 and a phase Ib/II trial studying the effect of avelumab with or without entinostat in patients with ovarian cancer https://www.clinicaltrials.gov/ct2/show/NCT02915523. Entinostat is also being studied in hormone receptor positive breast cancer in a phase III trial with endocrine therapy plus either entinostat or placebo https://www.clinicaltrials.gov/ct2/show/NCT02115282. KScientific (talk) 18:44, 18 January 2019 (UTC)KScientific

Revised content for proposed revision per feedback 15-Jan-2019

@Spintendo:

Change "There is an ongoing phase II trial studying the effect of entinostat on Hodgkin's lymphoma." to "A phase II trial studying the effect of entinostat on Hodgkin's lymphoma has been completed." using the same reference as currently cited.

After end of current content add:

There are also ongoing trials in lung cancer, melanoma, colorectal cancer, ovarian cancer and breast cancer. There are several studies investigating entinostat combined with checkpoint inhibitors. There is a phase Ib/II trial studying the effect of entinostat plus pembrolizumab on non-small cell lung cancer, melanoma and colorectal cancer patients. https://www.clinicaltrials.gov/ct2/show/NCT02437136. There is also a phase II trial studying the effect of atezolizumab with or without entinostat on triple negative breast cancer https://www.clinicaltrials.gov/ct2/show/NCT02708680 and a phase Ib/II trial studying the effect of avelumab with or without entinostat in patients with ovarian cancer https://www.clinicaltrials.gov/ct2/show/NCT02915523. Entinostat is also being studied in hormone receptor positive breast cancer in a phase III trial with endocrine therapy plus either entinostat or placebo https://www.clinicaltrials.gov/ct2/show/NCT02115282.

KScientific (talk) 18:10, 15 January 2019 (UTC)KScientific KScientific (talk) 17:24, 23 January 2019 (UTC)KScientific KScientific (talk) 16:07, 18 March 2019 (UTC)KScientific